XTX Topco’s MoonLake Immunotherapeutics MLTX Stock Holding History

XTX Topco’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.97M	Buy	152,472 +40,428	+36%	+$733K	0.04%	757
2026 Q1	$2.09M	Buy	112,044 +89,071	+388%	+$1.48M	0.04%	804
2025 Q4	$303K	Sell	22,973 -9,272	-29%	-$109K	0.01%	2056
2025 Q3	$231K	Buy	+32,245	New	+$1.68M	0.01%	1725
2025 Q2	–	Sell	-8,495	Closed	-$332K	–	2867
2025 Q1	$332K	Buy	+8,495	New	+$366K	0.02%	1324

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

XTX Topco's MLTX Position: Q2 2026 in Review

XTX Topco increased its MoonLake Immunotherapeutics (MLTX) stake by 36% in Q2 2026, buying an estimated $733K and bringing the position to 152,472 shares worth $2.97M. The position accounts for 0.04% of the portfolio, ranked #757.

XTX Topco first reported a position in MLTX in Q1 2025 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

XTX Topco held 152,472 shares of MoonLake Immunotherapeutics worth $2.97M as of Q2 2026.
XTX Topco bought 40,428 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $733K.
MoonLake Immunotherapeutics made up 0.04% of XTX Topco's portfolio in Q2 2026, its #757 holding.
XTX Topco first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 5 quarters since.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.